NeuroPace's (NPCE) Sell (D-) Rating Reiterated at Weiss Ratings

Key Points

• NeuroPace's stock received a "sell (D-)" rating from Weiss Ratings, indicating concerns about its performance.
• Wells Fargo reduced its target price on NeuroPace from $17.00 to $15.00 while maintaining an "overweight" rating, creating a contrasting perspective among analysts.
• The company's recent earnings report showed a loss of ($0.26) EPS, which was worse than the consensus estimate, despite reporting revenue above expectations.

NeuroPace (NASDAQ:NPCE - Get Free Report)'s stock had its "sell (d-)" rating reissued by Weiss Ratings in a note issued to investors on Saturday,Weiss Ratings reports.

NPCE has been the topic of several other reports. Wells Fargo & Company reduced their target price on NeuroPace from $17.00 to $15.00 and set an "overweight" rating on the stock in a report on Wednesday, August 13th. Zacks Research downgraded NeuroPace from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $16.60.

NeuroPace Stock Down 0.7%

Shares of NPCE opened at $10.48 on Friday. The company has a market capitalization of $346.68 million, a P/E ratio of -12.48 and a beta of 1.91. The company has a debt-to-equity ratio of 3.02, a current ratio of 5.47 and a quick ratio of 4.51. NeuroPace has a one year low of $5.45 and a one year high of $18.98. The business's 50 day simple moving average is $9.95 and its 200-day simple moving average is $10.87.

NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). The business had revenue of $23.52 million during the quarter, compared to analyst estimates of $23.08 million. NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%. NeuroPace has set its FY 2025 guidance at EPS. As a group, sell-side analysts predict that NeuroPace will post -1 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. lifted its stake in shares of NeuroPace by 83.6% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company's stock valued at $27,000 after purchasing an additional 1,118 shares during the period. Legal & General Group Plc lifted its stake in shares of NeuroPace by 86.0% in the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company's stock valued at $30,000 after purchasing an additional 1,239 shares during the period. Quantbot Technologies LP acquired a new position in shares of NeuroPace in the 2nd quarter valued at $35,000. Police & Firemen s Retirement System of New Jersey lifted its stake in shares of NeuroPace by 72.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 6,371 shares of the company's stock valued at $71,000 after purchasing an additional 2,668 shares during the period. Finally, AlphaQuest LLC acquired a new stake in NeuroPace during the 2nd quarter worth $82,000. Institutional investors and hedge funds own 78.83% of the company's stock.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.